Authorized Generics Study From FTC To Be Released Shortly
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC’s analysis of the competitive impact of authorized generics may be issued this month, just as a possible legislative vehicle for changes – a bill to ban “reverse payment” settlements – is gathering speed.
You may also be interested in...
Reverse Settlement Bill Clears House Subcommittee With GAO Report Attached
Legislation that would prohibit brand companies from compensating generic companies to delay entry of their generic drugs cleared the House Subcommittee on Commerce, Trade and Consumer Protection with a caveat: a Government Accountability Office report will keep tabs on whether the act results in earlier or delayed entry of generics to the market
Reverse Settlement Bill Clears House Subcommittee With GAO Report Attached
Legislation that would prohibit brand companies from compensating generic companies to delay entry of their generic drugs cleared the House Subcommittee on Commerce, Trade and Consumer Protection with a caveat: a Government Accountability Office report will keep tabs on whether the act results in earlier or delayed entry of generics to the market
Brand/Generic Settlement Bill May Need Help From Authorized Generics Limits
Supporters of legislation to curb settlements between brand and generic firms may consider modifying their proposal to include limits on authorized generics to garner more support